Skip to main content
. 2021 Aug 23;70(1):29–35. doi: 10.1136/jim-2020-001715

Figure 3.

Figure 3

Butyrate treatments affecting the myeloperoxidase (MPO) activities and malondialdehyde (MDA) levels after renal ischemia/reperfusion (I/R). Reduced MPO activities (A) and MDA levels (B) were observed in butyrate-treated rats (n=10/group, *p<0.05 vs the sham group, #p<0.05 vs the vehicle group). Data were shown as means±SD.